Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hefei
Clinical trial register · China

Clinical Trials in Hefei, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 131 Beijing 124 Shanghai 86 Changsha 72 Fuzhou 59
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca4 Pfizer3 Merck Sharp & Dohme LLC3 Shanghai Henlius Biotech2 Abbisko Therapeutics Co, Ltd2
Site location
Guangzhou131 Beijing124 Shanghai86 Changsha72 Fuzhou59
All 110 locations
Target enrolment
to

Trials with a site in Hefei

38 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Hefei, Beijing, Xiamen, Guangzhou, Guilin, Nanning, Shijiazhuang, Wuhan
2026-06-18
Not yet open
Anhui Provincial Cancer Hospital
Phase 2
154
Hefei
2026-06-06
Recruiting
AstraZeneca
Phase 4
100
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2026-05-26
Recruiting
RemeGen Co., Ltd.
Phase 3
574
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Dongguan, Guangzhou
2026-04-03
Recruiting
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Jiangmen, Nanning
2026-01-06
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Shantou
2025-12-17
Recruiting
Hoffmann-La Roche
Phase 3
600
Hefei, Nanchang, Hangzhou, Beijing, Bengbu, Changsha, Chengdu, Guangzhou
2025-10-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
Active, closed
Shanghai Henlius Biotech
Phase 1
174
Hefei, Wuhu, Beijing, Hunan, Fuzhou, Xiamen, Lanzhou, Cangzhou
2025-09-26
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
86
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2025-09-22
Recruiting
BioNTech SE
Phase 1/2
880
Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2025-09-22
Recruiting
Anhui Provincial Cancer Hospital
Not applicable
12
Hefei
2025-09-20
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
414
Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang
2025-09-02
Recruiting
AstraZeneca
Phase 2
278
Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei
2025-08-07
Recruiting
Pfizer
Phase 3
714
Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang
2025-07-23
Not yet open
Betta Pharmaceuticals Co., Ltd.
Phase 2
100
Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou
2025-03-31
Recruiting
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Active, closed
TJ Biopharma Co., Ltd.
Phase 2
150
Beijing, Binzhou, Chengdu, Chongqing, Ha’erbin, Hefei, Jiangmen, Kunming
2025-01-09
Recruiting
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou
2024-10-07
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi
2024-05-24
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
522
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang
2024-03-28
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
164
Hefei, Fuzhou, Xi'an, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-02-22
Active, closed
OncoC4, Inc.
Phase 3
630
Hefei, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Nanning, Haikou
2023-06-28
Active, closed
Shanghai Chest Hospital
Observational
305
Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai
2023-05-08
Active, closed
Hoffmann-La Roche
Phase 3
60
Beijing, Changsha, Chongqing, Fuzhou, Hangzhou, Hefei, Linyi, Nanjing
2022-06-14
Active, closed
A Study of AL8326 in Non-Small Cell Lung Cancer
NCT06794957Non-small Cell Lung Cancer
DrugAL8326
Advenchen Laboratories, LLC
Phase 1
158
Bengbu, Hefei, Xuancheng, Anyang, Zhengzhou, Wuhan, Nanjing, Hangzhou
2022-05-19
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
DrugsJAB-3312·Glecirasib
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Recruiting
AbbVie
Phase 3
768
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2022-03-25
Active, closed
AstraZeneca
Phase 3
1,051
Anyang, Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Hefei, Kunming
2022-02-07
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
BeiGene
Phase 3
453
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Jiangmen, Shantou
2020-05-29
Active, closed
AstraZeneca
Phase 3
825
Beijing, Changsha, Changzhou, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2018-12-06
Active, closed
AbbVie
Phase 2
270
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Zhengzhou
2018-10-10
Active, closed
Xcovery Holdings, Inc.
Phase 3
290
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanjing
2016-06
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangong Apt/Yuncheng, Hangzhou, Hefei
2016-05-24
Active, closed
Eli Lilly and Company
Phase 3
453
Beijing, Changchun, Changzhou, Chengdu, Haikou, Hangzhou, Hefei, Nanning
2014-10-03
Rows per page Showing 1–38 of 38
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-china/city/hefei

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 38 of those studies with a site in Hefei that also match the filters currently applied.

How many clinical trials are recruiting in Hefei?

21 of the 38 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hefei), 38 studies
PhaseStudiesRecruitingShare
Phase 3191250%
Phase 27318.4%
Phase 14010.5%
Phase 1/2337.9%
Observational215.3%
Phase 4215.3%
Not applicable112.6%

Most active sponsors

Lead sponsors with the most studies (Hefei)
Lead sponsorStudiesRecruiting
AstraZeneca42
Merck Sharp & Dohme LLC33
Pfizer32
Abbisko Therapeutics Co, Ltd21
AbbVie21
Anhui Provincial Cancer Hospital21
Hoffmann-La Roche21
Shanghai Henlius Biotech21
Advenchen Laboratories, LLC10
Allist Pharmaceuticals, Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.